Clinical Review

Breast density and optimal screening for breast cancer

Author and Disclosure Information

 

References

MY STORY: Epilogue

My annual 3D mammograms were normal, even the year my cancer was present. In 2014, I entered my family history into the IBIS Breast Cancer Risk Evaluation Tool (Tyrer-Cuzick model of breast cancer risk) (http://www.ems-trials.org/riskevaluator/) and calculated my lifetime risk at 19.7%. That is when I decided to have a screening MRI. My invasive breast cancer was easily seen on MRI and then on US. The cancer was node-negative, easily confirmed with needle biopsy, and treated with lumpectomy and radiation. There was no need for chemotherapy.

My personal experience prompted me to join JoAnn Pushkin and Cindy Henke-Sarmento, RT(R)(M), BA, in developing a website, www.DenseBreast-info.org, to give women and their physicians easy access to information on making decisions about screening in dense breasts.

My colleagues and I are often asked what is the best way to order supplemental imaging for a patient who may have dense breasts. Even in cases in which a mammogram does not exist or is unavailable, the following prescription can be implemented easily at centers that offer US: “2D plus 3D mammogram if available; if dense, perform ultrasound as needed.”

Related article:
DenseBreast-info.org: What this resource can offer you, and your patients

Breast density screening: Take advantage of today’s technology

Breast screening and diagnostic imaging have improved significantly since the 1970s, when many of the randomized trials of mammography were conducted. Breast density is one of the most common and important risk factors for development of breast cancer and is now incorporated into the Breast Cancer Surveillance Consortium model (https://tools.bcsc-scc.org/BC5yearRisk/calculator.htm) and the Tyrer-Cuzick model (see also http://densebreast-info.org/explanation-of-dense-breast-risk-models.aspx).32 Although we continue to validate newer approaches, women should take advantage of the improved methods of early cancer detection, particularly if they have dense breasts or are at high risk for breast cancer.

Share your thoughts! Send your Letter to the Editor to rbarbieri@frontlinemedcom.com. Please include your name and the city and state in which you practice.

Pages

Recommended Reading

2017 Update on female sexual dysfunction
MDedge ObGyn
FDA expands approval of fulvestrant for HR+/HER2– advanced breast cancer
MDedge ObGyn
Focus on lifestyle to manage menopause symptoms after breast cancer
MDedge ObGyn
FDA clears first 2D mammography device with patient-controlled compression
MDedge ObGyn
Ten-year outcomes support skipping axillary lymph node dissection with positive sentinel nodes
MDedge ObGyn
Surgeons strongly influenced chances of contralateral prophylactic mastectomy
MDedge ObGyn
LORELEI sings praises of neoadjuvant taselisib/letrozole in ER+/HER2– breast cancer
MDedge ObGyn
MONARCH 3: Abemaciclib plus AI boosts PFS in HR+/HER2- breast cancer
MDedge ObGyn
‘Very daring study’ of neoadjuvant AI/CDKi combo in early BC is hypothesis generating
MDedge ObGyn
GEICAM/2006-10: Adjuvant fulvestrant/anastrozole role in early breast cancer uncertain
MDedge ObGyn